National Employee Morale Day At Boston Scientific (BSX)

Health and Healthcare

Published: February 11, 2010 1:55 pm

Last Updated: February 11, 2010 5:12 pm

Boston Scientific (NYSE:BSX), the worst run of the large medical device and pharma firms based in the US, announced an operating loss for the fourth quarter of 2009 of $1.23 billion. The company’s guidance was poor which pushed shares down 7% in active trading to $7.61. The bad news was on top of an announcement last week that Boston Scientific will pay Johnson & Johnson (NYSE:JNJ) $1.7 billion to settle patent disputes. The New York Times wrote “The figure appears to be the largest sum ever paid to resolve patent litigation over a medical device.”

Boston Scientific also announced that it will cut 8% to 10% of its staff. The firm said the moves will save between $200 million and $250 million over the 2010 to 2011 period. It is the latest of a number of job cuts since the company bought Guidant in 2006.

It is difficult to see how CEO Ray Elliott will keep his job in the process. Elliott has only been with the company since last year, but the stock is down 40% during the last eight quarters. Elliott’s turnaround program has been a failure.

A great deal of the blame also goes to Pete M. Nicholas, the company’s co-founder, who has been Chairman of the Board since 1995. Boston Scientific shares traded for $12 in 1995, 40% more than the share price is now.

Douglas A. McIntyre

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.